Moreover, it was reported that preoperative IL-6 and CRP levels were higher in INTERMACS I patients scheduled for cfLVAD implantation, suggesting that patients with end-stage heart failure classified in a lower class of INTERMACS score (e.g., INTERMACS I or II) probably have a more pronounced disbalance in inflammatory biomarkers preoperatively with a probable worse outcome, such as vasoplegia and related early post-cfLVAD implantation complications, such as right ventricular failure and kidney failure [26]. This evidence concerns the gene CRP and kidney failure.